SOUTH SAN FRANCISCO, Calif., Sept. 20, 2016 (GLOBE NEWSWIRE) — Mateon Therapeutics, Inc. (Nasdaq:MATN), a clinical-stage biopharmaceutical company developing vascular disrupting agents for the treatment of orphan oncology indications, today announced it will present an overview of the company at the Ladenburg Thalmann 2016 Healthcare Conference on Tuesday, September 27, 2016 at 4:00 p.m. eastern time at the Sofitel New York.
To listen to a live webcast of the presentation, please visit the Company’s website, www.mateon.com. Under the “Investors & News” tab, select the link to “Events & Presentations.” A replay of the webcast will be available at this same location for a period of time following the conclusion of the live event.
Mateon Therapeutics, Inc. is a biopharmaceutical company seeking to realize the full potential of vascular targeted therapy (VTT) in oncology. VTT includes vascular disrupting agents (VDAs) such as the investigational drugs that Mateon is developing, and anti-angiogenic agents (AAs), a number of which are FDA-approved and widely used in cancer treatment. These two approaches have distinct yet complementary mechanisms of action.
At Mateon, we believe that we can significantly improve cancer therapy by employing these two complementary approaches simultaneously. When utilized this way, VDAs obstruct existing blood vessels in the tumor leading to significant central tumor cell death while AAs prevent the formation of new tumor blood vessels.
Mateon is committed to leveraging our intellectual property and the product development expertise of our highly skilled management team to enable VTT to realize its true potential and to bring much-needed new therapies to cancer patients worldwide.
CONTACT: CONTACT for investors and media: email@example.com 650-635-7000